Geron’s Board of Directors believes that sound governance practices and policies are important for our success as a
company and for ensuring alignment with our stockholders.
We are committed to ethical behavior by all of our employees, officers and directors. To promote ethical behavior, on
December 27, 2022, Geron amended and restated its Code of Conduct (the “Amended Code of Conduct”). The Amended Code of
Conduct is applicable to all employees, officers and directors of Geron. The Amended Code of Conduct replaces Geron’s
previous Code of Conduct (the “Prior Code”) in its entirety, to, among other things, reflect current industry and
public company best practices and enhance and expand on guiding principles and policies, including expanding
provisions related to (i) compliance with health care laws and regulations, (ii) product quality, pharmacovigilance
and regulatory compliance, and (iii) privacy and information security policies. The Amended Code of Conduct does not
result in any waiver with respect to any officer, director or employee of Geron from any provision of the Prior Code
as in effect prior to the amendment of the Prior Code.
Here we share with you our corporate governance guidelines, Amended Code of Conduct, Insider Trading Compliance
Program, and charters of each of the Board Committees, along with a list of our current Board of Directors and the
Board Committees on which they participate.
Stockholders wishing to contact Geron’s Board of Directors, may do so by writing c/o Secretary, Geron
Corporation, 919 E. Hillsdale, Suite 250, Foster City, CA 94404, or via email to Secretary@geron.com.